|  |  |  |  |
| --- | --- | --- | --- |
| Time interval from OCR to vaccine | 2nd vaccine | Time interval from OCR to vaccine | 3rd vaccine |
|  | Mean logIgG | Median logIgG | % sero-positive |  | Mean logIgG | Median logIgG | % sero-positive |
| <1mN=5≥1mN=81 | 0.897±0.4171.013± 0.126*p=0.92, F=0.01* | 0.2550.462 | 2/5(40%)23/81(28%) | <1mN=3≥1mN=39 | 01.408±0.236*p=0.37, F=0.825* | 00.663 | 1/1(0%)16/39(41%) |
| <2mN=16≥2mN=70 | 0.615±0.2071.087±0.139*p=0.42, F=0.66* | 0.230.607 | 3/16(19%)22/70(31%) | <2mN=3≥2mN=37 | 1.059±0.7651.398±0.246*p=0.75, F=0.10* | 0.6340.663 | 1/3(33%)15/37(41%) |
| <3m N=26≥3m N=60 | 0.894±0.2411.055±0.139*p=0.49, F=0.49* | 0.2410.695 | 7/26 (27%)18/60 (30%) | <3m N=5≥3m N=35 | 1.259±0.441.389±0.26*p=0.89, F=0.03* | 1.290.556 | 2/5(40%)14/35(40%) |
| <4m N=52≥4m N=34 | 0.939±0.1591.123±0.187*p=0.41, F=0.65* | 0.3610.843 | 13/52(25%)12/34(35%) | <4m N=15≥4m N=25 | 1.542±0.3851.272±0.297*p=0.57, F=0.34* | 1.290.556 | 6/15(40%)10/25(40%) |
| <5m N=70≥5m N=16 | 0.889±0.131.519±0.29***p=0.039****, F=4.43* | 0.3421.567 | 18/70(26%)7/16(44%) | <5m N=27≥5m N=13 | 1.031±0.2592.082±0.423***p=0.036,*** *F=4.76* | 0.4472.38 | 8/27(30%)8/13(62%) |
| <6m N=76≥6m N=10 | 0.909±0.1251.749±0.351***p=0.026****, F=5.19* | 0.3422.048 | 19/76(25%)6/10(60%) | <6m N=36≥6m N=4 | 1.214±0.2302.804±0.843***p=0.042****, F=4.43* | 0.5953.305 | 13/36(36%)3/4(75%) |

**Supplemental Table 2**

**IgG levels in ocrelizumab-treated patients according to the time interval between last treatment and vaccine.**

Comparison of IgG levels after 2nd or 3rd vaccine between patients with < or ≥ 1,2, 3, 4, 5 or 6 months time intervals between last ocrelizumab infusion and 1st or 3rd vaccination, using a general linear model adjusted for time between vaccination and blood collection. Seropositive border line: Log(50 AU/ml)= 1.699.

IgG- immunoglobulin G, m= months, OCR- ocrelizumab